SEKINE Ikuo

Researcher's full information

Articles
  • Knowledge of efficacy of treatments in lung cancer is not enough, their clinical effectiveness should also be known
    Sekine Ikuo
    J Thoracic Oncol/1(5)/pp.398-402, 2006-06
    PubMed
  • Common arm analysis: One approach to develop the basis for global standardization in clinical trials of non-small cell lung cancer
    Sekine Ikuo
    Lung Cancer/53(2)/pp.157-164, 2006-06
    PubMed
  • Docetaxel consolidation therapy following cisplatin, vinorelbine, and concurrent thoracic radiotherapy in patients with unresectable stage III non-small cell lung cancer
    Sekine Ikuo
    J Thorac Oncol/1(8)/pp.180-185, 2006-10
    PubMed
  • Phase I Study of Cisplatin Analogue Nedaplatin, Paclitaxel, and Thoracic Radiotherapy for Unresectable Stage III Non-Small Cell Lung Cancer
    Sekine Ikuo
    Jpn J Clin Oncol/37(3)/pp.175-180, 2007-04
  • Genes regulating the sensitivity of solid tumor cell lines to cytotoxic agents: a literature review
    Sekine Ikuo
    Jpn J Clin Oncol/37(5)/pp.329-336, 2007-05
    PubMed
  • Bodyweight change during the first 5 days of chemotherapy as an indicator of cisplatin renal toxicity
    Sekine Ikuo
    Cancer Sci/98(9)/pp.1408-1412, 2007-06
    PubMed
  • Problems with registration-directed clinical trials for lung cancer in Japan
    Sekine Ikuo
    Tohoku J Exp Med/213(1)/pp.17-23, 2007-09
  • Randomised phase II trial of irinotecan plus cisplatin vs irinotecan, cisplatin plus etoposide repeated every 3 weeks in patients with extensive-disease small-cell lung cancer
    Sekine Ikuo
    Br J Cancer/98(4)/pp.693-696, 2008-2
    PubMed
  • Local control of regional and metastatic lesions and indication for systemic chemotherapy in patients with non-small-cell lung cancer
    Sekine Ikuo
    Oncologist/13 (Suppl 1)/pp.21-27, 2008-01
    PubMed
  • Risk factors for skeletal-related events in patients with non-small cell lung cancer treated by chemotherapy.
    Sekine Ikuo
    Lung Cancer/65(2)/pp.219-222, 2008-12
    PubMed
  • Emerging ethnic differences in lung cancer therapy
    Sekine Ikuo
    Br J Cancer/99(11)/pp.1757-1762, 2008-04
    PubMed
  • Is there a need to take ethnicity into account when considering lung cancer treatment?
    Sekine Ikuo
    Expert Rev Respir Med/3(1)/pp.1-4, 2009-02
    PubMed
  • Quality of life and disease-related symptoms in previously treated Japanese patients with non-small-cell lung cancer: results of a randomized phase III study (V-15-32) of gefitinib versus docetaxel
    Sekine Ikuo
    Ann Oncol/20(9)/pp.1483-1488, 2009-03
    PubMed
  • Comparative chemotherapeutic efficacy in non-small cell lung cancer patients with postoperative recurrence and stage IV disease
    Sekine Ikuo
    J Thorac Oncol/4(4)/pp.518-512, 2009-04
    PubMed
  • A literature review of molecular markers predictive of clinical response to cytotoxic chemotherapy in patients with breast cancer
    Sekine Ikuo
    Int J Clin Oncol/14(2)/pp.112-119, 2009-04
    PubMed
  • Innovator and generic cisplatin formulations: comparison of renal toxicity
    Sekine Ikuo
    Cancer Sci/102(1)/pp.162-165, 2010-11
    PubMed
  • Phase I study of concurrent high-dose three-dimensional conformal radiotherapy with chemotherapy using cisplatin and vinorelbine for unresectable stage III non-small cell lung cancer
    Sekine Ikuo
    Int J Radiat Oncol Biol Phys/82(2)/pp.953-959, 2011-04
    PubMed
  • Risk factors of chemotherapy-induced nausea and vomiting: index for personalized antiemetic prophylaxis
    Sekine Ikuo
    Cancer Sci/104(6)/pp.711-717, 2013-04
    PubMed
  • Clinical classification of targeted agents used for anticancer treatment.
    Sekine Ikuo
    Tohoku J Exp Med/230(1)/pp.1-5, 2013-04
    PubMed
  • A randomized phase III study of single-agent amrubicin vs. carboplatin/etoposide in elderly patients with extensive-disease small-cell lung cancer
    Sekine Ikuo
    Clin Lung Cancer/15(2)/pp.96-102, 2013-11
    PubMed